AUSTIN, Texas, July 30, 2015 /PRNewswire/ — Vermillion, Inc. (VRML), a bio-analytical solutions company focused on gynecologic disease, announced today it will report its second quarter 2015 financial results after the market close on Thursday, August 13, 2015, followed by an investor conference call and webcast at 4:30pm Eastern.
|Conference Call and Webcast:|
|Thursday, August 13, 2015 at 4:30pm Eastern/1:30pm Pacific|
|Replay – available through August 27, 2015|
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, have diagnostic programs in gynecologic disease. The company’s lead diagnostic, OVA1®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.
Investor Relations Contact:
LifeSci Advisors LLC
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vermillion-to-report-second-quarter-2015-financial-results-and-host-investor-conference-call-on-august-13-300120535.html
SOURCE Vermillion, Inc.